Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries

PROCEPT BioRobotics Corporation - Common Stock (NQ:PRCT)

20.56 -0.65 (-3.06%)
Streaming Delayed Price Updated: 12:44 PM EDT, Jul 7, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 398,728
Open 21.39
Bid (Size) 20.52 (800)
Ask (Size) 20.60 (400)
Prev. Close 21.21
Today's Range 20.26 - 21.72
52wk Range 19.35 - 62.17
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
PROCEPT BioRobotics® Advances Prostate Cancer Program with WATER IV Study Enrollment Completion and Expanded IDE Approval
From PROCEPT BioRobotics
Via GlobeNewswire
News headline image
What to Know About This Fund's $10 Million Nektar Bet Ahead of a Key Phase 3 Launch ↗
Biotech firm Nektar Therapeutics advances a pipeline of immunology and oncology candidates through research-driven collaborations. 
Via The Motley Fool

Performance

YTD
-33.2%
-33.2%
1 Month
-27.5%
-27.5%
3 Month
-13.5%
-13.5%
6 Month
-37.9%
-37.9%
1 Year
-63.9%
-63.9%

More News

Read More
News headline image
This Healthcare Investor Added $43 Million to a Genomics Leader Growing Volume 34% ↗
Via The Motley Fool
Topics Artificial Intelligence
PROCEPT BIOROBOTICS CORP (NASDAQ:PRCT) Q1 Earnings Beat Drives 13% Surge Despite Net Loss ↗
Via Chartmill
Topics Earnings
News headline image
5 Robotics Stocks to Watch as Physical AI Builds Momentum ↗
Via MarketBeat
Topics Artificial Intelligence
News headline image
AUA Guidelines Strengthen Recommendation for Aquablation® Therapy
From PROCEPT BioRobotics
Via GlobeNewswire
News headline image
PROCEPT BioRobotics® to Attend Three Upcoming Investor Conferences in May & June
From PROCEPT BioRobotics
Via GlobeNewswire
News headline image
Procept (PRCT) Q1 2026 Earnings Transcript ↗
Via The Motley Fool
Topics Artificial Intelligence
What's going on in today's after hours session ↗
Via Chartmill
News headline image
PROCEPT BioRobotics Reports First Quarter 2026 Financial Results
From PROCEPT BioRobotics
Via GlobeNewswire
News headline image
Chicago Capital Doubles Down on PROCEPT BioRobotics, Adds $27 Million in Stock ↗
Via The Motley Fool
News headline image
Securities Fraud Investigation Into PROCEPT BioRobotics Corporation (PRCT) Continues – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
From Glancy Prongay Wolke & Rotter LLP
Via Business Wire
News headline image
PROCEPT BioRobotics Corporation (PRCT) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
From Law Offices of Howard G. Smith
Via Business Wire
News headline image
Securities Fraud Investigation Into PROCEPT BioRobotics Corporation (PRCT) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
From The Law Offices of Frank R. Cruz
Via Business Wire
News headline image
PROCEPT BioRobotics (PRCT) Earnings Transcript ↗
Via The Motley Fool
Topics World Trade
News headline image
PROCEPT BioRobotics® to Report First Quarter 2026 Financial Results on April 29, 2026
From PROCEPT BioRobotics
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PROCEPT BioRobotics Corporation - PRCT
From Pomerantz LLP
Via GlobeNewswire
News headline image
EAU Guidelines Upgrade Aquablation® Therapy to Strong Surgical Recommendation for BPH
From PROCEPT BioRobotics
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PROCEPT BioRobotics Corporation - PRCT
From Pomerantz LLP
Via GlobeNewswire
News headline image
PROCEPT BioRobotics® Announces International Launch of the HYDROS® Robotic System, Expanding Global Access to AI-Enabled Aquablation® Therapy
From PROCEPT BioRobotics
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PROCEPT BioRobotics Corporation - PRCT
From Pomerantz LLP
Via GlobeNewswire
News headline image
Securities Fraud Investigation Into PROCEPT BioRobotics Corporation (PRCT) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
From Glancy Prongay Wolke & Rotter LLP
Via Business Wire
News headline image
PROCEPT BioRobotics Corporation (PRCT) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
From Law Offices of Howard G. Smith
Via Business Wire
News headline image
Securities Fraud Investigation Into PROCEPT BioRobotics Corporation (PRCT) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
From The Law Offices of Frank R. Cruz
Via Business Wire
News headline image
PRCT Investors Have Opportunity to Join PROCEPT BioRobotics Corporation Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire

Frequently Asked Questions

Is PROCEPT BioRobotics Corporation - Common Stock publicly traded?
Yes, PROCEPT BioRobotics Corporation - Common Stock is publicly traded.
What exchange does PROCEPT BioRobotics Corporation - Common Stock trade on?
PROCEPT BioRobotics Corporation - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for PROCEPT BioRobotics Corporation - Common Stock?
The ticker symbol for PROCEPT BioRobotics Corporation - Common Stock is PRCT on the Nasdaq Stock Market
What is the current price of PROCEPT BioRobotics Corporation - Common Stock?
The current price of PROCEPT BioRobotics Corporation - Common Stock is 20.56
When was PROCEPT BioRobotics Corporation - Common Stock last traded?
The last trade of PROCEPT BioRobotics Corporation - Common Stock was at 07/07/26 12:44 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.